CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2007-04-11): Scoring system predicts fibrosis in liver disease patients

Clinical

Scoring system predicts fibrosis in liver disease patients

Last Updated: 2007-04-11 10:10:21 -0400 (Reuters Health)

NEW YORK (Reuters Health) - A scoring system that incorporates six variables can accurately identify patients with nonalcoholic fatty liver disease (NAFLD) who also have advanced fibrosis, new research shows. Use of this system could greatly reduce the number of patients requiring liver biopsy, the authors believe.

NAFLD patients with advanced fibrosis are at increased risk for progressing to end-stage liver disease, which can have treatment implications, lead author Dr. Paul Angulo, from the Mayo Clinic in Rochester, Minnesota, and colleagues note. However, at present, liver biopsy is the only reliable method of identifying such patients.

The goal of the present study was to come up with a noninvasive method of predicting advanced fibrosis with NAFLD. To do this, the researchers created a scoring system by examining the predictive ability of several routinely measured clinical and laboratory values in 733 patients with biopsy-confirmed NAFLD. The system was created using data from 480 of the patients and then was validated in the remaining 253.

The new findings appear in the April issue of Hepatology.

The researchers identified six independent predictors of advanced liver fibrosis: age, hyperglycemia, BMI, platelet count, albumin, and AST/ALT ratio. The scoring system derived from these variables had an area under the receiver operating characteristic curve of 0.88 and 0.82 in the system-generation and -validation cohorts, respectively.

Depending on the cutoff score employed, positive and negative predictive values of up to 90% and 93%, respectively, were achieved. Use of the scoring system could have prevented liver biopsy in 75% of all patients with accurate prediction in 90%, the authors state.

Further studies are needed to determine if the predictive value of the scoring system could be improved by including serum markers of fibrosis and imaging results, the researchers conclude.

Hepatology 2007;45:846-854.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.